Wednesday, 26th of April 2017 |
Nutrients. 2017 Feb 24;9(3). pii: E190. doi: 10.3390/nu9030190.
Vitamin A Supplementation Programs and Country-Level Evidence of Vitamin A Deficiency
Wirth JP1, Petry N2, Tanumihardjo SA3, Rogers LM4, McLean E5, Greig A6, Garrett GS7, Klemm RD8,9, Rohner F10.
Abstract below; full text is at http://www.mdpi.com/2072-6643/9/3/190
Vitamin A supplementation (VAS) programs targeted at children aged 6-59 months are implemented in many countries. By improving immune function, vitamin A (VA) reduces mortality associated with measles, diarrhea, and other illnesses. There is currently a debate regarding the relevance of VAS, but amidst the debate, researchers acknowledge that the majority of nationally-representative data on VA status is outdated. To address this data gap and contribute to the debate, we examined data from 82 countries implementing VAS programs, identified other VA programs, and assessed the recentness of national VA deficiency (VAD) data. We found that two-thirds of the countries explored either have no VAD data or data that were >10 years old (i.e., measured before 2006), which included twenty countries with VAS coverage ≥70%. Fifty-one VAS programs were implemented in parallel with at least one other VA intervention, and of these, 27 countries either had no VAD data or data collected in 2005 or earlier. To fill these gaps in VAD data, countries implementing VAS and other VA interventions should measure VA status in children at least every 10 years. At the same time, the coverage of VA interventions can also be measured. We identified three countries that have scaled down VAS, but given the lack of VA deficiency data, this would be a premature undertaking in most countries without appropriate status assessment. While the global debate about VAS is important, more attention should be directed towards individual countries where programmatic decisions are made.
KEYWORDS:
MNPs; biofortification; deficiency; fortification; programs; supplementation; vitamin A
PMID:
28245571
PMCID:
DOI:
Images from this publication.See all images (1)Free text
PubMed Commons
0 comments
Supplemental Content
Full text links
Save items
Add to FavoritesView more options
Similar articles
Cited by 1 PubMed Central article
Related information
Recent Activity
ClearTurn Off
PubMed
PubMed
PubMed
You are here: NCBI > Literature > PubMed
Simple NCBI Directory
National Center for Biotechnology Information, U.S. National Library of Medicine8600 Rockville Pike, Bethesda MD, 20894 USA
Policies and Guidelines | Contact
Bottom of Form
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
40951993 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |